Antineoplastics (BCR-ABL TKIs)
- Target BCR-ABL in Philadelphia+ leukemia
- Transformative therapy for chronic-phase CML
- Imatinib is historic prototype
- Later TKIs overcome resistance/intolerance
- Toxicities differ: vascular, pleural, QT, metabolic
- CYP3A interactions are common
- Response is followed with molecular BCR-ABL
Class at a glance
- Target BCR-ABL in Philadelphia+ leukemia
Practical pearls
- Imatinib is historic prototype
Pharmacology
- CYP3A interactions are common
Members / distinctions
- Transformative therapy for chronic-phase CML
- Later TKIs overcome resistance/intolerance
- Response is followed with molecular BCR-ABL
Safety / monitoring
- Toxicities differ: vascular, pleural, QT, metabolic
Self-check
- What major toxicities vary among BCR-ABL TKIs?
Vascular, pleural, QT, and metabolic toxicities.
- How is BCR-ABL TKI response followed?
Molecular BCR-ABL testing.
Drugs in this class (5)
All drug classes · Open the interactive console ↗
